Sophiris Bio Inc.

(PTXRF)

By |

Profile

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations are functioned through the regions of Canada.

Contact Information

Website: www.sophirisbio.com
Email: ir@sophirisbio.com
Main Phone: +1 858 777-1760
Address: 1258 Prospect Street
State: CA
City / Town: La Jolla
Country: USA
Postal Code: 92037

Issuer Information

Exchange: GREY
CEO: Randall E. Woods
Employees: 6
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 30,111,153.00 EPS (TTM) -0.55 PE Ratio N/A Exchange Greys
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 4 4 4 4
Low Target Price Estimate 4 4 4 4
Mean Target Price Estimate 4 4 4 4
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 05/23/16 05/23/16 05/23/16 05/23/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1